Last reviewed 2026-04-20 · How we verify

Parinase (GLYPINAMIDE)

Phase 2 active Small molecule Quality 19/100

Parinase (generic name: GLYPINAMIDE) is a glypinamide drug. It is currently in Phase 2 development.

Parinase works by modulating ion channels in the nervous system.

Parinase (GLYPINAMIDE) is a small molecule drug in the glypinamide class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. There is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Parinase is not listed as an off-patent or generic medication. Further research is needed to understand its clinical use and safety profile.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLYPINAMIDE
Drug class	glypinamide
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your nerve cells are like electrical wires. Parinase helps control the flow of electrical signals by adjusting the channels that allow these signals to pass through. This can help regulate various bodily functions, but the exact details of how it works are still unclear.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Parinase CI brief — competitive landscape report
Parinase updates RSS · CI watch RSS

Frequently asked questions about Parinase

What is Parinase?

Parinase (GLYPINAMIDE) is a glypinamide drug.

How does Parinase work?

Parinase works by modulating ion channels in the nervous system.

What is the generic name of Parinase?

GLYPINAMIDE is the generic (nonproprietary) name of Parinase.

What drug class is Parinase in?

Parinase belongs to the glypinamide class. See all glypinamide drugs at /class/glypinamide.

What development phase is Parinase in?

Parinase is in Phase 2.

Drug class: All glypinamide drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing